AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cimetidine 100 mg/h
Number of subjects: 10
Study 1091130 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 IU alpha-tocopherol acetate daily for 6 months
Number of subjects: 0
Study 1091130 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 0
Study 1091130 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 IU alpha-tocopherol acetate daily
Number of subjects: 0
Study 31455249 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL ropivacaine 0.75%
Number of subjects: 20
Study 31455249 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mL ropivacaine 0.75%
Number of subjects: 20
Study 31455249 — intervention group
Group type: COMPARATOR
Intervention: Both groups (8 mL and 16 mL)
Number of subjects: 20
Study 28207537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis (IL) approach
Number of subjects: 136
Study 28207537 — intervention group
Group type: COMPARATOR
Intervention: Left transthoracic (LTT) approach
Number of subjects: 136
Study 28207537 — intervention group
Group type: EXPERIMENTAL
Intervention: Left thoracoabdominal (LTA) approach
Number of subjects: 136
Study 26306966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise programme (E) during HD sessions
Number of subjects: 22
Study 26306966 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) receiving standard HD care
Number of subjects: 22
Study 23736966 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 0.25 to 4.5 mg/kg
Number of subjects: 80
Study 23736966 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 1.5 mg/kg after fasting
Number of subjects: 80
Study 23736966 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 3.0 mg/kg
Number of subjects: 80
Study 23736966 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS)
Number of subjects: 80
Study 21208945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber minimal ventricular pacing (MinVP)
Number of subjects: 66
Study 21208945 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual chamber pacing (DDDR)
Number of subjects: 66
Study 19520544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL)
Number of subjects: 66
Study 19520544 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 mL, Control)
Number of subjects: 66
Study 17848841 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin Powder (Sandoz)
Number of subjects: 140
Study 17848841 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin Solution (Sandoz)
Number of subjects: 140
Study 17848841 — intervention group
Group type: COMPARATOR
Intervention: Reference rhGH preparation
Number of subjects: 140
Study 15025216 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) plus acellular dermal matrix (ADM) allograft
Number of subjects: 24
Study 15025216 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF) alone
Number of subjects: 24
Study 11831591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate with a glucose concentration of 5.5 mmol/L
Number of subjects: 20
Study 11831591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate with a glucose concentration of 11 mmol/L
Number of subjects: 20
Study 9693573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite and 0.2% chlorhexidine gluconate combined
Number of subjects: 10
Study 9693573 — intervention group
Group type: COMPARATOR
Intervention: 2.5% sodium hypochlorite alone
Number of subjects: 10
Study 9693573 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate alone
Number of subjects: 10
Study 9693573 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10
Study 7602838 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of Surfactant‐TA
Number of subjects: 0
Study 7602838 — intervention group
Group type: COMPARATOR
Intervention: Surfactant‐TA
Number of subjects: 0
Study 2966139 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg and 200 mg regimens)
Number of subjects: 49
Study 2966139 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (500 mg qds for five days) and Tobramycin (1.5 mg/kg initially then 80 mg tds for three days)
Number of subjects: 49
Study 329948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, Bendrofluazide, and Hydralazine (twice daily)
Number of subjects: 39
Study 329948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (added to Bendrofluazide or Bendrofluazide plus Atenolol)
Number of subjects: 39
Study 329948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Bendrofluazide (once daily)
Number of subjects: 39
Study 329948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 39
Study 31599225 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 20 mg
Number of subjects: 40
Study 31599225 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 40 mg
Number of subjects: 40
Study 31599225 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 80 mg
Number of subjects: 40
Study 31599225 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 160 mg
Number of subjects: 40
Study 31599225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27621272 — intervention group
Group type: EXPERIMENTAL
Intervention: PAIN RelieveIt Trial intervention (details not specified)
Number of subjects: 223
Study 27621272 — intervention group
Group type: COMPARATOR
Intervention: Screening and eligibility process
Number of subjects: 223
Study 25179585 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided surgery
Number of subjects: 60
Study 25179585 — intervention group
Group type: COMPARATOR
Intervention: Non-guided surgery
Number of subjects: 60
Study 23447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of carvedilol 25-mg
Number of subjects: 23
Study 23447077 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of carvedilol 25-mg
Number of subjects: 23
Study 22226371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual tablet, initial dose 100 μg, titrated to effective dose of 100 to 800 μg.
Number of subjects: 270
Study 20667679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 340
Study 20667679 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 340
Study 17707822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 56
Study 17707822 — intervention group
Group type: COMPARATOR
Intervention: Transobturator suburethral tape (TVT-O) procedure
Number of subjects: 56
Study 15814550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-3 HLA mismatches (MM)
Number of subjects: 180
Study 15814550 — intervention group
Group type: COMPARATOR
Intervention: 4-6 HLA mismatches (MM)
Number of subjects: 180
Study 12479764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/d
Number of subjects: 10355
Study 12479764 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study 9657188 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy without fusion
Number of subjects: 91
Study 9657188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion with autologous bone graft
Number of subjects: 91
Study 9657188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion with autologous bone graft plus plating
Number of subjects: 91
Study 8154412 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment (2 gm/L of drinking water) for 20 days after late reperfusion
Number of subjects: 67
Study 8154412 — intervention group
Group type: COMPARATOR
Intervention: Late reperfusion (reperfusion 2 hours after left coronary artery ligation)
Number of subjects: 67
Study 8154412 — intervention group
Group type: COMPARATOR
Intervention: Myocardial infarction (MI) with no treatment
Number of subjects: 67
Study 2776168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30
Study 2776168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study 273021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential t test in experimental clinical trials
Number of subjects: 0
Study 273021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential t test
Number of subjects: 0
Study 273021 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of subjects with consistent caries increments
Number of subjects: 0
Study 31170812 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB/β-TCP-collagen
Number of subjects: 104
Study 31170812 — intervention group
Group type: COMPARATOR
Intervention: autograft
Number of subjects: 104
Study 28453240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based ART with cotrimoxazole prophylaxis
Number of subjects: 156
Study 28453240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based ART
Number of subjects: 156
Study 25753869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mm locking plate (group A, n = 30)
Number of subjects: 60
Study 25753869 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mm non-locking plate (group B, n = 30)
Number of subjects: 60
Study 23511357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (20 sessions)
Number of subjects: 100
Study 23511357 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (600 mg/day)
Number of subjects: 100
Study 21055502 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg hemagglutinin (HA)
Number of subjects: 454
Study 21055502 — intervention group
Group type: COMPARATOR
Intervention: 15 μg hemagglutinin (HA)
Number of subjects: 454
Study 21055502 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg HA
Number of subjects: 454
Study 21055502 — intervention group
Group type: COMPARATOR
Intervention: 15 μg HA
Number of subjects: 454
Study 21055502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 30 μg HA and 15 μg HA
Number of subjects: 454
Study 21055502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 454
Study 19369375 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum BB536 and Lactobacillus rhamnosus GG; BB536‐LGG)
Number of subjects: 94
Study 19369375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 16464538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated and accelerated radiochemotherapy (RCT) with 5-fluorouracil (600 mg/m²/day) and carboplatin (70 mg/m²/day) on Days 1-5 and 29-33, total RT dose of 69.9 Gy in 38 days.
Number of subjects: 0
Study 16464538 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated and accelerated radiotherapy (RT) alone, total RT dose of 69.9 Gy in 38 days.
Number of subjects: 0
Study 14625604 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 100
Study 14625604 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 100
Study 14625604 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (on-demand therapy)
Number of subjects: 100
Study 14625604 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (on-demand therapy)
Number of subjects: 100
Study 11192489 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 54
Study 11192489 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + SSZ
Number of subjects: 54
Study 9071477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate (400 mg/day orally)
Number of subjects: 12
Study 9071477 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (400 mg/day orally)
Number of subjects: 12
Study 8373973 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 20
Study 2872470 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (COP plus doxorubicin)
Number of subjects: 739
Study 2872470 — intervention group
Group type: COMPARATOR
Intervention: COP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 739
Study 2872470 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 739
Study 2872470 — intervention group
Group type: COMPARATOR
Intervention: COP regimen
Number of subjects: 739
Study 29053230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Four monthly face‐to‐face biofeedback treatments
Number of subjects: 350
Study 29053230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: One face‐to‐face biofeedback followed by telephone biofeedback
Number of subjects: 350
Study 29053230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: One face‐to‐face biofeedback followed by telephone biofeedback
Number of subjects: 350
Study 29053230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: One‐off face‐to‐face biofeedback treatment
Number of subjects: 350
Study 29053230 — intervention group
Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 350
Study 27011304 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions)
Number of subjects: 120
Study 27011304 — intervention group
Group type: COMPARATOR
Intervention: Surgical release/decompression of the carpal tunnel
Number of subjects: 120
Study 27011304 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy
Number of subjects: 120
Study 24142187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low financial motivation group
Number of subjects: 0
Study 24142187 — intervention group
Group type: EXPERIMENTAL
Intervention: High financial motivation group
Number of subjects: 0
Study 22873565 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 (telemetry device-based follow-up)
Number of subjects: 40
Study 22873565 — intervention group
Group type: COMPARATOR
Intervention: G1 (office-based follow-up)
Number of subjects: 40
Study 20054669 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-oriented individualized induction therapy with idarubicin (IDR) 12 mg/m2 for 3 days and cytarabine (Ara-C) 100 mg/m2 for 7 days, with additional IDR and Ara-C if bone marrow on day 8 did not become hypocellular with less than 15% blasts.
Number of subjects: 430
Study 20054669 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule induction therapy with idarubicin (IDR) 12 mg/m2 for 3 days and cytarabine (Ara-C) 100 mg/m2 for 7 days.
Number of subjects: 430
Study 20054669 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-oriented individualized induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Number of subjects: 430
Study 20054669 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Number of subjects: 430
Study 17999182 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model accommodating overdispersion and clustering through random effects (gamma and normal types)
Number of subjects: 0
Study 17999182 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation with fully analytic integration and hybrid integration
Number of subjects: 0
Study 16118575 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (750 mg daily for 10 days)
Number of subjects: 16
Study 16118575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose polymer, daily for 10 days)
Number of subjects: 16
Study 12399761 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment, 3 times per week for up to 8 weeks
Number of subjects: 20
Study 12399761 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment
Number of subjects: 20
Study 12399761 — intervention group
Group type: COMPARATOR
Intervention: Control plaque (not treated)
Number of subjects: 20
Study 10435212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LO) 2 mg
Number of subjects: 21
Study 10435212 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (OX) 60 mg
Number of subjects: 21
Study 10435212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LO)
Number of subjects: 21
Study 10435212 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (OX)
Number of subjects: 21
Study 7796951 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing the major EBV membrane antigen BNLF-1 MA (gp 220-340)
Number of subjects: 9
Study 7796951 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated infants)
Number of subjects: 9
Study 1690202 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (1 pmol.kg‐1.min‐1)
Number of subjects: 6
Study 1690202 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (5 micrograms.kg‐1.min‐1)
Number of subjects: 6
Study 1690202 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (6 pmol.kg‐1.min‐1)
Number of subjects: 6
Study 1690202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 311679 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 23
Study 311679 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX/BCG
Number of subjects: 23
Study 311679 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of HDMTX
Number of subjects: 23
Study 311679 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 23
Study 31272903 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil counts
Number of subjects: 9789
Study 31272903 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS identified rs4713354 variant (MDC1 on chromosome 6p21)
Number of subjects: 9789
Study 31272903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of subjects with elevated eosinophil counts
Number of subjects: 9789
Study 31136545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (30% 1RM)
Number of subjects: 23
Study 31136545 — intervention group
Group type: COMPARATOR
Intervention: High-load resistance training (80% 1RM)
Number of subjects: 23
Study 31136545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low-load and high-load resistance training
Number of subjects: 23
Study 28322360 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP
Number of subjects: 54
Study 28322360 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP with 0.2% NaF (CPP-ACFP)
Number of subjects: 54
Study 24938661 — intervention group
Group type: EXPERIMENTAL
Intervention: Iosimenol injection
Number of subjects: 144
Study 24938661 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol injection
Number of subjects: 144
Study 23742912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 17
Study 23742912 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine + Tenofovir (FTC/TDF)
Number of subjects: 17
Study 21461896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal contact point surgery (septoplasties or submucous resections with or without partial turbinectomies)
Number of subjects: 42
Study 21461896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal contact point surgery
Number of subjects: 42
Study 19139053 — intervention group
Group type: EXPERIMENTAL
Intervention: Primigravidae
Number of subjects: 642
Study 19139053 — intervention group
Group type: COMPARATOR
Intervention: Multigravidae
Number of subjects: 642
Study 16395516 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA measurements using Analycor 3 analyzer; TBW calculated from impedances at 50 and 100 kHz, ECW from impedance at 5 kHz.
Number of subjects: 36
Study 16395516 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA age specific equations
Number of subjects: 36
Study 16395516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 36
Study 14507232 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox® (total dose 20 biological units)
Number of subjects: 537
Study 14507232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 10427937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy-affected persons
Number of subjects: 100
Study 10427937 — intervention group
Group type: COMPARATOR
Intervention: Unaffected individuals (Control)
Number of subjects: 100
Study 10427937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy-affected women
Number of subjects: 100
Study 10427937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy-affected males with deformities
Number of subjects: 100
Study 10427937 — intervention group
Group type: EXPERIMENTAL
Intervention: Leprosy-affected females with deformities
Number of subjects: 100
Study 10427937 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic status
Number of subjects: 100
Study 8960843 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.33 microgram.min-1.dl-1)
Number of subjects: 12
Study 8960843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1922860 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of fentanyl (group A)
Number of subjects: 28
Study 1922860 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of fentanyl (group B)
Number of subjects: 28
Study 1922860 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 micrograms of fentanyl (group C)
Number of subjects: 28
Study 1922860 — intervention group
Group type: COMPARATOR
Intervention: Saline (group D)
Number of subjects: 28
Study 6805499 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 23
Study 30296169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reappraisal
Number of subjects: 279
Study 30296169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-is-debilitating
Number of subjects: 279
Study 30296169 — intervention group
Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 279
Study 28064433 — intervention group
Group type: EXPERIMENTAL
Intervention: Niobe™ ES magnetic navigation system
Number of subjects: 386
Study 28064433 — intervention group
Group type: COMPARATOR
Intervention: Manual procedure
Number of subjects: 386
Study 27382592 — intervention group
Group type: EXPERIMENTAL
Intervention: Self care education
Number of subjects: 75
Study 27382592 — intervention group
Group type: EXPERIMENTAL
Intervention: Self care education plus telephone follow-up
Number of subjects: 75
Study 27382592 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 75